Phaseline

Companies › Berlin-Chemie AG Menarini Group

Berlin-Chemie AG Menarini Group: clinical trials, targets and expected readouts

2 active drug programs in 16 registered trials: 6 Phase 1, 5 Phase 4, 3 Phase 3, 2 Phase 2; Other, Genitourinary, Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tamsulosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 1Healthy Volunteers; Healthy Adult Males Volunteers; Healthy Volunteer Male Subjects; Nephrolithiasis …–
Torasemide tablet 10 mg
Loop diuretic - inhibits Na-K-2Cl cotransporter
SLC12A2Phase 1Healthy Adult Male and Female Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07091669TamsulosinPhase 1Healthy VolunteersOtherAug 2025
NCT07146711TamsulosinPhase 1Healthy Adult Males VolunteersOtherOct 2025
NCT07201584Torasemide tablet 10 mgPhase 1Healthy Adult Male and Female VolunteersOtherDec 2025
NCT07124299TamsulosinPhase 4NephrolithiasisGenitourinaryJan 2026
NCT06843538TamsulosinPhase 3Postoperative Urinary Retention (POUR)OtherFeb 2026
NCT07156916TamsulosinPhase 1Healthy Volunteer Male SubjectsOtherMar 2026
NCT04147806TamsulosinPhase 1Prostate CancerOncologyJul 2026
NCT06737016TamsulosinPhase 3Posterior Urethral ValveOtherNov 2026
NCT04597372TamsulosinPhase 2Urinary Retention PostoperativeOtherDec 2026
NCT06001619TamsulosinPhase 4Prostatic HyperplasiaOncologyDec 2026
NCT07815379TamsulosinPhase 4BPH (Benign Prostatic Hyperplasia)GenitourinaryJan 2027
NCT03609580TamsulosinPhase 1Urinary RetentionOncologyMar 2027
NCT07623876TamsulosinPhase 2Renal StonesGenitourinaryApr 2027
NCT07650968TamsulosinPhase 4Acute Urinary RetentionGenitourinaryMay 2027
NCT06966804TamsulosinPhase 3Stent Related SymptomsOtherMay 2027
NCT07310797TamsulosinPhase 4Ureteral CalculiGenitourinaryDec 2029

Targets

ADRA1A (1) ADRA1D (1) ADRA1B (1) SLC12A2 (1)

Companies with the same targets

Santen SAS Opus Genetics Applied Biology ARS Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.